Autolus Therapeutics plc (NASDAQ:AUTL) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET

Company Participants

Olivia Manser - Director, Investor Relations

Christian Itin - Chief Executive Officer

Lucinda Crabtree - Chief Financial Officer

Conference Call Participants

Mara Goldstein - Mizuho

Matthew Phipps - William Blair

James Shin - Wells Fargo Securities

Gil Blum - Needham & Company

Operator

Hello ladies and gentlemen and welcome to the Autolus Therapeutics Third Quarter 2022 Financial Results Conference Call. As a reminder, this conference call is being recorded.

And I'd like to now turn the conference over to your host Olivia Manser Director of Investor Relations. Please go ahead.

Olivia Manser

Thanks Breanna. Good morning or good afternoon everyone and thanks for joining us to take part in today's call on the financial results and operational highlights for the third quarter for Autolus. I'm Olivia Manser, Director of Investor Relations. And with me on today's call as usual are Dr. Christian Itin, our Chief Executive Officer; and Dr. Lucinda Crabtree, our Chief Financial Officer.

So, before we begin, I'd just like to remind you as usual that during today's call our discussion will contain forward-looking statements. Please make sure you are familiar with our disclaimer slide which is on slide two.

And then turning to slide three, you'll see the agenda for today which is as follows. Christian will provide an update of our operational highlights for the third quarter of 2022. Lucinda will then discuss the company's financial results, before Christian will conclude with the upcoming milestones and any other concluding comments. And finally we will of course welcome your questions.

Over to you Christian.

Christian Itin

Thank you, Olivia. Good morning to you all and thank you for joining us. It's my pleasure to review our progress for the third quarter 2022.

Moving to slide four, we're really pleased with our strategic and operational progress during the third quarter of 2022, which is highlighted over the next two slides. Firstly, we remain on track to provide an update on our pivotal FELIX trial in Q4 2022 and we plan to present FELIX Phase 2 data at a medical conference in the first half of 2023 most likely at ASCO.

We're also looking forward to presenting longer follow-up data from our ALL patients in the OLCAR19 Phase 1 trial at ASH and are looking forward at the patients that we've treated with non-Hodgkin's lymphoma.